Acs Fall 2024 Vvd-130037 Vvd1300375
Acs Fall 2024 Vvd-130037 Vvd1300375. Vividion therapeutics, inc., confirmed the commencement of patient dosing for a phase i cancer clinical trial concerning its experimental oral agent, keap1 activator. Trial participants…